{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Vadimezan",
  "nciThesaurus": {
    "casRegistry": "117570-53-3",
    "chebiId": "",
    "chemicalFormula": "C17H14O4",
    "definition": "A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF-alpha), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis.  This agent also stimulates the anti-tumor activity of tumor-associated macrophages.",
    "fdaUniiCode": "0829J8133H",
    "identifier": "C2504",
    "preferredName": "Vadimezan",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C306"
    ],
    "synonyms": [
      "5,6-Dimethylxanthenone-4-Acetic Acid",
      "5,6-MexXAA",
      "ASA404",
      "DMXAA",
      "Dimethyloxoxanthene Acetic Acid",
      "Dimethylxanthenone Acetic Acid",
      "VADIMEZAN",
      "Vadimezan",
      "dimethylxanthenone acetic acid"
    ]
  }
}